

Newsletter

Lund 12 February 2024

New order received for the Innovative TSE Cancer Treatment Technology

Scandinavian ChemoTech's Animal Care division has received an order for USD 30,000 from one of its largest clients in the United States. The order is for an additional vetIQure™ TSE (Tumour Specific Electroporation™) system, an innovative and minimally invasive treatment for various types of cancers in animals.

In less than a year, the Animal Care division has received orders for five vetIQure TSE systems and several treatment kits from one single account. The vetIQure TSE system is a patented solution designed to improve clinical outcomes for veterinarians treating cancer and is produced for veterinary use only. It provides the veterinarians with a precise and minimally invasive method to administer chemotherapy directly into solid tumours and helps to maximise its effect whilst minimising damage to surrounding healthy tissue.

This targeted therapy is developed to reduce risks for ablations and destruction and to stimulate the patient's own immune system to attack the tumour cells and can therefore lead to better outcomes with fewer side effects for the animals

"We are delighted to receive another order for our vetIQure TSE system, especially from such an esteemed provider," says Mohan Frick, CEO of Scandinavian ChemoTech. "This further validates our innovative and gentle approach to cancer treatment. We look forward to continuing to partner with leading veterinary groups to make this life-changing technology available to more animals in need of care."

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.